B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAP3K5

MOLECULAR TARGET

mitogen-activated protein kinase kinase kinase 5

UniProt: Q99683NCBI Gene: 421712 compounds

MAP3K5 (mitogen-activated protein kinase kinase kinase 5) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAP3K5

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1at 92833.0921
2lestaurtinib3.0420
3hymenialdisine3.0019
4k 252a2.8316
5mli 22.6413
6selonsertib2.4811
7y 399832.208
8amg 9002.087
9pf 038147351.795
10fisetin0.691
11Quercetin0.691
12sp6001250.691

About MAP3K5 as a Drug Target

MAP3K5 (mitogen-activated protein kinase kinase kinase 5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented MAP3K5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAP3K5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.